Cardiol Therapeutics (CRDL, Financial) has caught the attention of H.C. Wainwright, which has launched coverage on the company with a Buy recommendation and a price target of $9. As a clinical-stage firm, Cardiol Therapeutics is making strides in the development of therapies aimed at reducing inflammation and fibrosis in heart disease. Currently, the company is advancing its CardiolRx program, focusing on treatments for recurrent pericarditis and acute myocarditis.
The firm’s optimism is rooted in the potential value that Cardiol Therapeutics may reveal as their clinical programs progress. Investors are encouraged to consider the promising prospects that these developments could bring to the company and its stock.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Cardiol Therapeutics Inc (CRDL, Financial) is $10.07 with a high estimate of $10.07 and a low estimate of $10.07. The average target implies an upside of 705.33% from the current price of $1.25. More detailed estimate data can be found on the Cardiol Therapeutics Inc (CRDL) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, Cardiol Therapeutics Inc's (CRDL, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
